<DOC>
	<DOCNO>NCT01086228</DOCNO>
	<brief_summary>The objective post-marketing surveillance , conduct Japan , know frequency , type degree device malfunction , assure safety medical device , collect information evaluation efficacy safety .</brief_summary>
	<brief_title>XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol Japan</brief_title>
	<detailed_description>The surveillance conduct accordance Japanese Ministerial Ordinance concerning Standards Postmarketing Surveillance Tests Medical Devices .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Only XIENCE V stent ( ) PROMUS stent ( ) ( ) implant coronary vasculature index procedure . Neither XIENCE V stent ( ) PROMUS stent ( ) ( ) implant coronary vasculature index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
</DOC>